Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Dow
Medtronic
Colorcon

Last Updated: March 30, 2020

DrugPatentWatch Database Preview

OPTISON Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Optison, and what generic alternatives are available?

Optison is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-seven countries.

The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

US ANDA Litigation and Generic Entry Outlook for Optison

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 20, 2021. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for OPTISON
Drug Prices for OPTISON

See drug prices for OPTISON

Generic Entry Opportunity Date for OPTISON
Generic Entry Date for OPTISON*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OPTISON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Chiltern International Inc.Phase 4
National Cancer Institute (NCI)Early Phase 1
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityEarly Phase 1

See all OPTISON clinical trials

Synonyms for OPTISON
1,1,1,2,2,3,3,3-Octafluoropropane
1,1,1,2,2,3,3,3-octakis(fluoranyl)propane
76-19-7
A838638
AKOS006228213
C-50894
C3F8
C3F8-gas
CHEBI:31980
CHEMBL1663
CK0N3WH0SR
CTK5E2580
D01738
DB-056033
DB00556
Definity
Definity (TN)
DMP 115
DMP-115
DTXSID9052503
EC 200-941-9
EINECS 200-941-9
FC 218
FC 218 (refrigerant)
FCH918400
Freon 218
FS-069
FS-6566
FS069
FT-0621948
FT-0631321
Genetron 218
HFC 218
HSDB 8074
liposome-encapsulated perfluoropane microsphere
LS-120891
MRX 115
MRX-115
OCTAFLUOROPROPANE
octafluoropropane-lipid microsphere
Octafluoropropaneor Refrigerant gas R 218
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluorpropan
Oktafluorpropan
Optison (Salt/Mix)
Perfluoropropane
Perflutren
Perflutren (JAN/USAN/INN)
Perflutren [USAN:INN:BAN]
Perflutren [USAN]
Perflutren and Human Albumin
Perflutren Lipid Microsphere
Perflutren lipid microspheres
Perflutren Protein-Type A Microspheres injection
Perflutren-lipid microsphere
PFC 218
Propane, 1,1,1,2,2,3,3,3-octafluoro-
Propane, octafluoro-
Propane,1,1,1,2,2,3,3,3-octafluoro-
Q412659
QYSGYZVSCZSLHT-UHFFFAOYSA-N
R 218
SBB090673
UN 2424
UN2424
UNII-CK0N3WH0SR
YM454
ZINC8214651
ZX-AP010865

US Patents and Regulatory Information for OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997   Start Trial   Start Trial
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997   Start Trial   Start Trial
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for OPTISON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1853250 132014902271575 Italy   Start Trial PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220
1853250 122014000065 Germany   Start Trial PRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
1853250 C300673 Netherlands   Start Trial PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
0961612 2009C/046 Belgium   Start Trial PRODUCT NAME: PACLITAXEL ALBUMIN; AUTHORISATION NUMBER AND DATE: EU/1/07/428/001 20080111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Dow
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.